Introduction to the Skye Bioscience Class Action Lawsuit

Skye Bioscience class action lawsuit

How Securities Class Actions Work

  • A lead plaintiff files the Skye Bioscience class action lawsuit:  Usually, an individual or institutional investor who suffered a large financial loss acts as the lead plaintiff, representing the interests of all investors who were harmed. The lawsuit is typically brought by a law firm that specializes in securities litigation.
  • The Skye Bioscience class action lawsuit proceeds through the court. The case is filed under federal or state securities laws, like the Securities Exchange Act of 1934. The defendant company may file a motion to dismiss the case. If the case proceeds, both sides will enter a lengthy discovery phase to gather evidence.
  • Most cases end in a settlement. Rather than going to trial, the company often agrees to pay a sum of money into a common fund to be distributed to the class. The court must approve the fairness of any settlement.
  • Claims are administered. If a settlement is reached, a claims administrator is appointed to process claims and distribute funds to eligible investors. The entire process, from filing the complaint to distributing funds, can take several years. 

Common Types of Misconduct

  • Securities fraud class actions: Can arise from various types of misconduct by a company, its officers, or others involved in the sale of its securities, including:
    • Making false or misleading statements in SEC filings, prospectuses, or earnings announcements.
    • Overstating a company’s revenues or profits through fraudulent or “creative” accounting.
    • Failing to disclose material information that would significantly alter an investor’s view.
    • Engaging in market manipulation to artificially inflate or deflate a security’s price. 

The Allegations in the Skye Bioscience Class Action Lawsuit

Overview

  • Skye Bioscience: is a clinical stage biopharmaceutical company that focuses on developing molecules to treat obesity, overweight, and metabolic diseases.
  • According to the Complaint: In August 2024, Skye Bioscience initiated its “CBeyond” clinical trial, a twenty-six-week, randomized, double-blind, placebo-controlled Phase 2a proof-of-concept study designed to assess Skye Bioscience’s nimacimab product candidate as a treatment for obesity and overweight.

False and Misleading Statements

The Skye Bioscience class action lawsuit alleges that throughout the Class Period defendants made false and/or misleading statement and/or failed to disclose that:

  • (i)  Nimacimab was less effective than defendants had led investors to believe; and
  • (ii) Accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated.

October 6, 2025, Announcement

  • The Skye Bioscience class action lawsuit: Alleges that on October 6, 2025, Skye Bioscience announced topline data from the CBeyond clinical trial, disclosing that the “the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo” and that “preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy.”
  • On this News: The price of Skye Bioscience stock fell 60%, according to the complaint.

The Private Securities Reform Act of 1995?

  • Private Securities Litigation Reform Act (PSLRA) of 1995: Is a significant piece of legislation in the United States that was designed to curb frivolous or unwarranted securities lawsuits. This reform act was enacted to address the rampant abuse in securities class action litigation, which was seen as detrimental to businesses and the economy.
  • Higher Pleading Standards: By establishing more stringent requirements for plaintiffs, the PSLRA aims to discourage baseless lawsuits while preserving investors’ rights to seek redress for legitimate grievances. One of the key provisions of the PSLRA includes the imposition of a higher standard for pleading securities fraud, requiring plaintiffs to specify each statement alleged to be misleading and the reasons why it is misleading. Additionally, it introduced the “safe harbor” provision for forward-looking statements, protecting companies from liability if they have made clear cautionary statements.

Avantor Class Action Lawsuit

  • Lead Plaintiff Selection: The PSLRA also changes how lead plaintiffs are selected in class action lawsuits. It favors institutional investors or individuals with significant financial interests in the securities at issue, under the assumption that these plaintiffs will have the resources and incentives to represent the class effectively. This act has had a profound impact on how securities litigation is conducted in the United States, aiming to balance the scales between protecting investors and preventing abuse of the legal system.
  • Complexity: In light of recent events, where companies face numerous legal challenges, such as the Skye Bioscience class action lawsuit, understanding and navigating the complexities of the PSLRA becomes crucial. The reforms brought by this act are particularly relevant in today’s financial landscape, ensuring that while businesses are shielded from unfounded claims, investors still have avenues to seek justice against genuine instances of fraud or misconduct. The PSLRA continues to play a pivotal role in shaping securities litigation and maintaining fairness in financial markets.

Skye Bioscience class action lawsuit

The Lead Plaintiff Deadline in the Skye Bioscience Class Action Lawsuit

​​​Lead plaintiff motions for the Skye Bioscience class action lawsuit  must be filed with the court no later than January 16, 2026. When a securities class action is filed such as the Skye Bioscience class action lawsuit :

  1. The person who files the first complaint is required to publish a notice announcing the filing.
  2. Anyone who wants to be lead plaintiff on behalf of the class must thereafter file a motion to be appointed as lead plaintiff(s) no later than 60 days after the notice was published.

The Lead Plaintiff Process in the Skye Bioscience Class Action Lawsuit

The Private Securities Litigation Reform Act of 1995 (PSLRA) permits any investor who purchased and suffered losses in Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”) to move for lead plaintiff.

The Benefits of Serving as a Lead Plaintiff in the Skye Bioscience Class Action Lawsuit

  1. Negotiating more competitive attorney fees and reducing litigation costs.
  2. Managing the litigation by overseeing the progress of the case and reviewing important filings.
  3. Participating in mediation and settlement discussions.
  4. Having a voice in decision-making processes regarding the settlement.
  5. No financial risk, as lead counsel covers all costs and expenses and are paid only if they secure a  settlement or judgment recovery for the class
  6. Potentially enjoying long-term benefits from governance reform resulting from the litigation.

The Responsibilities the Lead Plaintiff Will Have in the Skye Bioscience Class Action Lawsuit

  1. Negotiating more competitive attorney fees and reducing litigation costs.​
  2. Managing the litigation by overseeing the progress of the case and reviewing important filings.
  3. Participating in mediation and settlement discussions.
  4. Having a voice in decision-making processes regarding the settlement.
  5. No financial risk, as lead counsel covers all costs and expenses and are paid only if they secure a  settlement or judgment recovery for the class
  6. Potentially enjoying long-term benefits from governance reform resulting from the litigation.

 

The Eligibility Criteria for Lead Plaintiff Appointment in the Skye Bioscience Lawsuit

To be eligible for appointment as the lead plaintiff in the Skye Bioscience class action lawsuit, an investor must meet the following criteria:

  • Securities Acquisition: The investor must have been purchasers or acquirers of Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”).
  • Financial Losses: The investor must have suffered financial losses as a direct result of the alleged securities fraud perpetrated by Avantor and its executives.

It is crucial to note that both domestic and international investors who meet these criteria are eligible to seek appointment as the lead plaintiff in the class action lawsuit, as courts have consistently recognized the rights of non-U.S. investors in securities class actions.

 How the Greatest Financial Interest Determined in the Skye Bioscience Class Action Lawsuit

  • Greatest Financial Interest: In the Skye Bioscience class action lawsuit determining the greatest financial interest among plaintiffs is a critical aspect that influences the course and outcome of the litigation. This determination typically involves assessing various factors such as the total monetary losses incurred, the volume of shares traded, and the overall impact of the alleged misconduct on each plaintiff’s investment. Legal experts and financial analysts collaborate to evaluate these elements meticulously.
  • Determining Damages: They employ sophisticated financial models to calculate the extent of damages and compare them across all plaintiffs involved in the Skye Bioscience class action lawsuit. The plaintiff with the greatest financial interest is often given priority in leading the lawsuit, as their substantial losses signify a significant stake in achieving a favorable resolution.
  • Vital Role of Lead Plaintiff: Moreover, court-appointed lead plaintiffs play a vital role in representing the interests of all affected parties. The selection process for these lead plaintiffs is governed by statutory criteria established under laws such as the PSLRA. This legislation emphasizes the importance of appointing plaintiffs who possess the largest financial interest and can adequately represent the class
  • Enhancing Collective Action: In the context of the Skye Bioscience class action lawsuit this ensures that those who have suffered considerable financial harm are at the forefront of legal proceedings, thereby enhancing the effectiveness of collective action. Ultimately, determining the greatest financial interest is not merely a matter of quantifying losses but also ensuring that justice is served equitably among all parties involved in the lawsuit.

What Plaintiffs Must Prove

To succeed in a federal securities fraud class action, plaintiffs must prove several elements:

  • Material misstatement or omission: The company made a false or misleading statement, or failed to disclose a material fact.
  • Scienter: The defendant acted with an intent to deceive, manipulate, or defraud.
  • Reliance: The plaintiff relied on the misstatement or omission when buying or selling the security. For publicly traded securities, this can be proven through the “fraud-on-the-market” theory, which presumes the market price reflects all public, material information.
  • Economic loss: The plaintiff suffered a financial loss. 
  • Loss causation: The company’s misstatement or omission directly caused the plaintiff’s loss, often demonstrated by a stock price drop after the truth is revealed in a “corrective disclosure”

Benefits for Investors

  • Participating in a class action allows like the Skye Bioscience class action lawsuit allows investors to pool their resources, which offers leverage they would not have in an individual lawsuit against a large corporation.
  • The collective approach also makes it more efficient and cost-effective to pursue legal action, especially for smaller investors.

Skye Bioscience class action lawsuit

How to Get Involved in the Skye Bioscience Class Action Lawsuit

  • If you bought a security during the alleged class period and suffered a loss, you are generally automatically included in the class. You don’t have to take any action unless you want to file a claim for recovery later.
  • You may be notified of a class action by mail if you are an eligible class member.
  • You may be able to become a lead plaintiff by applying within 60 days of the first lawsuit being announced.
  • If you believe you may have a claim, you can contact a securities class action law firm for guidance.

You Can Sell Your Stock and Still be a Part of the Skye Bioscience Class Action Lawsuit?

  • Eligible if Sold Stock: If you have sold your stock, you may still be eligible to participate in the Skye Bioscience class action lawsuit. The eligibility to be part of a class action lawsuit typically depends on whether you were a shareholder during the period of the alleged wrongdoing and suffered a loss, rather than your current status as a shareholder. Therefore, if you held stock in Stride during the period specified in the lawsuit and meet other criteria established by the court or legal team, you may still have a valid claim.
  • Consult a Lawyer: It is advisable to consult with a legal professional who specializes in securities litigation to understand your rights and the steps you need to take to join the lawsuit. This ensures that you can potentially recover any losses you might have incurred due to the actions that are being contested in the Skye Bioscience class action lawsuit.

It Does Not Cost Anything to Hire a Lawyer in the Skye BioscienceClass Action Lawsuit?

Gathering and Organizing Relevant Evidence

To build a case and prove financial loss, investors should gather all documentation related to their investments during the class period.
Investment records:
  • Transaction confirmations: These slips confirm when securities were purchased and at what price.
  • Account statements: Your brokerage or custodian account statements show transaction logs, purchases, sales, and holdings.
  • Purchase and sale documentation: Records of all transactions for the relevant securities, including the amount and duration of holdings.
Public company materials:
  • Financial statements: Annual reports, 10-K filings, quarterly reports, and 10-Q filings, which are used to identify misrepresentations or omissions.
  • Prospectuses and registration statements: These documents, issued in connection with public offerings, may contain material misstatements or omissions.
  • Press releases and public announcements: These can help identify public, material misrepresentations made by the company.
  • Internal communications: Emails, memos, meeting minutes, and other communications relevant to the alleged fraud.
  • Public notices: Class action notices and settlement details should be monitored and gathered.
Supporting evidence:
  • Expert opinions: Expert reports and testimony are often necessary to analyze market data and financial statements.
  • Testimony: This includes sworn affidavits or deposition transcripts from witnesses.

Frequently Asked Questions About the Skye Bioscience Class Action Lawsuit

What initiated the Skye Bioscience class action lawsuit?

The Skye Bioscience class action lawsuit was initiated by investors alleging that Avantor provided misleading information regarding its financial health and operations, resulting in financial losses.

How can I join the Skye Bioscience class action lawsuit?

If you purchased shares during the class period and suffered a loss, then you are automatically a member of the Skye Bioscience class action lawsuit and do not need to do anything at this point unless you are considering moving for lead plaintiff.

What are the potential benefits of a Skye Bioscience class action lawsuit?

Class action lawsuits like the Skye Bioscience class action lawsuit allow individual investors to collectively seek justice and compensation, which might be challenging to pursue individually. They also promote corporate accountability.

How long will the Skye Bioscience class action lawsuit take to resolve?

The duration of class action lawsuits can vary significantly, depending on the complexity of the case, legal strategies, and whether settlements are reached. It could take several months to years to resolve the lawsuit.

Contact Timothy L. Miles Today About a Skye Bioscience Class Action Lawsuit

The most important thing you need to know is you can call me at no charge if you wish to serve as lead plaintiff of the Skye Bioscience class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling  855/846-6529 or via e-mail at [email protected].(24/7/365).

Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com

Facebook    Linkedin    Pinterest    youtube

 

 

 

Logo law office timothy l. miles used in Skye Bioscience class action lawsuit